002907 华森制药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.9203.8844.6822.0266.842
总资产报酬率 ROA (%)1.6143.3004.0721.7595.409
投入资产回报率 ROIC (%)1.8503.7964.6572.0176.269

边际利润分析
销售毛利率 (%)59.93557.38757.27454.97859.335
营业利润率 (%)17.76711.36012.1066.62613.860
息税前利润/营业总收入 (%)16.4508.59710.6644.91614.161
净利润/营业总收入 (%)13.6466.6759.9034.72812.532

收益指标分析
经营活动净收益/利润总额(%)91.87976.65080.25384.08191.697
价值变动净收益/利润总额(%)4.41512.5161.474-10.910-2.407
营业外收支净额/利润总额(%)-0.102-21.311-0.384-7.071-0.544

偿债能力分析
流动比率 (X)4.6794.2694.8644.7424.528
速动比率 (X)4.1513.7434.2033.9383.985
资产负债率 (%)14.69215.78413.43112.61313.729
带息债务/全部投入资本 (%)0.5830.643-2.047-2.368-2.329
股东权益/带息债务 (%)16,568.21014,970.585-4,851.382-4,206.132-4,275.219
股东权益/负债合计 (%)576.723528.585644.531692.802628.379
利息保障倍数 (X)-12.661-11.201-7.638-3.86537.741

营运能力分析
应收账款周转天数 (天)82.64778.35679.963100.52587.211
存货周转天数 (天)142.999142.557158.660154.033136.536